H Mucke

Summary

Affiliation: HM Pharma Consultancy
Country: Austria

Publications

  1. ncbi TAK-147 (Takeda)
    H Mucke
    HM Pharma Consultancy, Wien, Austria
    Curr Opin Investig Drugs 2:1595-9. 2001
  2. ncbi Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas
    Hermann A M Mucke
    HM Pharma Consultancy, Wien, Austria
    IDrugs 12:366-75. 2009
  3. ncbi Pulmonary arterial hypertension: on the way to a manageable disease
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    Curr Opin Investig Drugs 9:957-62. 2008
  4. ncbi New ocular therapeutics: a view from the patenting perspective
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    IDrugs 10:37-41. 2007
  5. ncbi Current drug patenting for retinal diseases: beyond VEGF inhibitors
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    IDrugs 13:30-7. 2010
  6. ncbi Therapies in development for the treatment of migraine
    Hermann Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Vienna, Austria
    Expert Opin Investig Drugs 11:1813-20. 2002
  7. ncbi Frovatriptan Vernalis
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    Curr Opin Investig Drugs 3:1373-80. 2002
  8. ncbi CEP-1347 (Cephalon)
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Vienna, Austria
    IDrugs 6:377-83. 2003
  9. ncbi Neurology--18th world congress. 5-11 November 2005, Sydney, Australia
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria
    IDrugs 9:19-22. 2006
  10. ncbi Cardiovascular developments: patent highlights July to December 2006
    Hermann A M Mucke
    HM Pharma Consultancy, Enelkelstrasse 28 32, A 1160 Wein, Austria
    Curr Opin Investig Drugs 8:193-200. 2007

Detail Information

Publications16

  1. ncbi TAK-147 (Takeda)
    H Mucke
    HM Pharma Consultancy, Wien, Austria
    Curr Opin Investig Drugs 2:1595-9. 2001
    ..By November 1999, it had entered phase III trials in Japan [348496]. In August 1999, Lehman Brothers predicted product launch in 2002, with potential peak sales of $250 million in 2012 [349228]...
  2. ncbi Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas
    Hermann A M Mucke
    HM Pharma Consultancy, Wien, Austria
    IDrugs 12:366-75. 2009
    ..Marketed and advanced-stage endothelin receptor blockers have remarkably little chemical diversity; thus, the substantially larger chemical space defined by patenting remains to be explored...
  3. ncbi Pulmonary arterial hypertension: on the way to a manageable disease
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    Curr Opin Investig Drugs 9:957-62. 2008
    ..Benefits in survival and quality-of-life will decide if any of the more experimental approaches that utilize newly discovered molecular pathways in PAH will ultimately result in marketed drugs...
  4. ncbi New ocular therapeutics: a view from the patenting perspective
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    IDrugs 10:37-41. 2007
    ..The role of RNA interference, which is of particular interest in ophthalmology research, is also highlighted...
  5. ncbi Current drug patenting for retinal diseases: beyond VEGF inhibitors
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    IDrugs 13:30-7. 2010
    ..Diabetic retinopathy has not received as much attention from inventors compared with AMD; retinopathy of prematurity remains a field in which little specific patenting occurs...
  6. ncbi Therapies in development for the treatment of migraine
    Hermann Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Vienna, Austria
    Expert Opin Investig Drugs 11:1813-20. 2002
    ..The broadest potential, however, lies in a better understanding of the molecular pharmacology of migraine...
  7. ncbi Frovatriptan Vernalis
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    Curr Opin Investig Drugs 3:1373-80. 2002
    ..Vanguard (now Vernalis) has developed frovatriptan, a selective 5-HT1B/1D partial agonist licensed from GlaxoSmithKline as a potential treatment for migraine [188478], [194382], [377863]...
  8. ncbi CEP-1347 (Cephalon)
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Vienna, Austria
    IDrugs 6:377-83. 2003
  9. ncbi Neurology--18th world congress. 5-11 November 2005, Sydney, Australia
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria
    IDrugs 9:19-22. 2006
  10. ncbi Cardiovascular developments: patent highlights July to December 2006
    Hermann A M Mucke
    HM Pharma Consultancy, Enelkelstrasse 28 32, A 1160 Wein, Austria
    Curr Opin Investig Drugs 8:193-200. 2007
    ..This objective was met by replicating the previous search of Thomson Scientific's Investigational Drugs database, and by using the same categorization of identified intellectual property disclosures...
  11. ncbi Cardiovascular and renal developments: patent highlights January to June 2006
    Hermann A M Mucke
    HM Pharma Consultancy, Wien, Austria
    Curr Opin Investig Drugs 7:792-8. 2006
    ..This summary highlights the most interesting developments seen in cardiovascular and renal patents (other than those claiming formulations or combinations of known drugs) published during the first half of 2006...
  12. ncbi Genomics-based cardiovascular drug development: the challenges are just beginning
    Hermann A M Mucke
    Curr Opin Investig Drugs 7:203-5. 2006
  13. ncbi Rotigotine Schwarz Pharma
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28 32, A 1160 Wien, Austria
    IDrugs 6:894-9. 2003
    ....
  14. ncbi The European Association of Addiction Therapy - Inaugural Conference
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28/32, Wien, Austria
    IDrugs 8:816-7. 2005
  15. ncbi Tumor progression & therapeutic resistance--Second International Conference
    Hermann A M Mucke
    HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria
    IDrugs 8:894-7. 2005
  16. ncbi The failing heart as a drug target: are we finally seeing progress?
    Hermann A M Mucke
    Curr Opin Investig Drugs 6:870-3. 2005